• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲和澳大利亚的口腔白斑病诊断和治疗:口腔医学从业者的态度和实践。

Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practitioners' attitudes and practice.

机构信息

Department of Oncology, Oral Medicine and Oral Oncology Unit, University of Turin, Turin, Italy.

Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy.

出版信息

Oral Dis. 2023 Nov;29(8):3214-3222. doi: 10.1111/odi.14301. Epub 2022 Jul 14.

DOI:10.1111/odi.14301
PMID:35792047
Abstract

The management of oral potentially malignant disorders (OPMD) including oral leukoplakia (OL) is not currently structured according to agreed guidelines. The current report presents survey data gathered from Oral Medicine Practitioners (OMPs) in Europe and Australia and is aimed to investigate attitudes and practice in the diagnosis, risk stratification and treatment of OL. In the presence of a clinical provisional diagnosis of OL, respondents reported always undertaking biopsy in 83% of cases, with most OMPs also relying on diagnostic adjuncts. The potential for malignant transformation is almost invariably assessed through epithelial dysplasia status, with other biomarkers described in the literature used less often. Active treatment of OL was considered mandatory by 20% of OMPs, while others reserve treatment for selected cases only. OMPs are mostly driven to active treatment by lesion-related features which are frequently jointly considered including lesion site, clinical appearance and dysplasia status. Inconsistent assessment was observed regarding mild dysplasia, lesion size, presence of unavoidable trauma, exposure to tobacco and patient age. Frequently observed geographical variations were seldom statistically significant. In agreement with previous surveys, a lack of consensus around the management of OL was observed, supporting claims from learned academies and societies for treatment guidelines aiming to reduce inter-practitioner variability.

摘要

口腔潜在恶性疾病(OPMD)的管理,包括口腔白斑(OL),目前尚未按照既定指南进行规范。本报告介绍了从欧洲和澳大利亚口腔医学从业者(OMPs)收集的调查数据,旨在调查他们对 OL 的诊断、风险分层和治疗的态度和实践。在临床初步诊断为 OL 的情况下,受访者报告在 83%的情况下始终进行活检,大多数 OMPs 还依赖诊断辅助手段。通过上皮异型增生状态评估恶性转化的可能性几乎是不变的,文献中描述的其他生物标志物则较少使用。20%的 OMPs认为必须对 OL 进行积极治疗,而其他 OMPs 则仅将治疗保留给选定的病例。OMPs 主要受到病变相关特征的驱动,这些特征通常包括病变部位、临床外观和异型增生状态等因素。在轻度异型增生、病变大小、不可避免的创伤、烟草暴露和患者年龄等方面,评估存在不一致性。经常观察到的地理差异很少具有统计学意义。与之前的调查一致,观察到 OL 管理方面缺乏共识,这支持了学术机构和学会提出的治疗指南的要求,旨在减少从业者之间的差异。

相似文献

1
Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practitioners' attitudes and practice.欧洲和澳大利亚的口腔白斑病诊断和治疗:口腔医学从业者的态度和实践。
Oral Dis. 2023 Nov;29(8):3214-3222. doi: 10.1111/odi.14301. Epub 2022 Jul 14.
2
Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients.口腔白斑恶变:218 例中国患者的回顾性队列研究。
BMC Cancer. 2010 Dec 16;10:685. doi: 10.1186/1471-2407-10-685.
3
[Oral medicine 8. Leukoplakia of the oral mucosa].[口腔医学8.口腔黏膜白斑病]
Ned Tijdschr Tandheelkd. 2013 Jul-Aug;120(7-8):384-90.
4
Treatment of Oral Dysplasia.口腔发育异常的治疗。
Dent Clin North Am. 2024 Jan;68(1):133-149. doi: 10.1016/j.cden.2023.07.008. Epub 2023 Aug 23.
5
Oral leukoplakia classification and staging system with incorporation of differentiated dysplasia.纳入分化型发育异常的口腔白斑分类与分期系统。
Oral Dis. 2023 Oct;29(7):2667-2676. doi: 10.1111/odi.14295. Epub 2022 Jul 7.
6
[Research progress in the diagnosis and management of proliferative verrucous leukoplakia].[增殖性疣状白斑的诊断与治疗研究进展]
Zhonghua Kou Qiang Yi Xue Za Zhi. 2023 Oct 9;58(10):1083-1090. doi: 10.3760/cma.j.cn112144-20230816-00088.
7
Oral premalignant lesions: from a clinical perspective.口腔癌前病变:从临床角度看。
Int J Clin Oncol. 2011 Feb;16(1):5-14. doi: 10.1007/s10147-010-0157-3. Epub 2011 Jan 12.
8
Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England.在英格兰东南部,经过 10 年的时间,有哪些因素可以预测口腔潜在恶性疾病患者的恶性转化。
J Oral Pathol Med. 2011 Oct;40(9):677-83. doi: 10.1111/j.1600-0714.2011.01054.x. Epub 2011 Jul 18.
9
Oral potentially malignant disorders: risk of progression to malignancy.口腔潜在恶性疾病:进展为恶性肿瘤的风险
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):612-627. doi: 10.1016/j.oooo.2017.12.011. Epub 2017 Dec 29.
10
[Clinicopathological characteristics of malignant transformation in 85 cases of oral leukoplakia].85例口腔白斑恶变的临床病理特征
Zhonghua Kou Qiang Yi Xue Za Zhi. 2012 Jul;47(7):410-3. doi: 10.3760/cma.j.issn.1002-0098.2012.07.008.

引用本文的文献

1
Deep Learning-Based Automated Detection of Oral Leukoplakia in Clinical Imaging.基于深度学习的临床影像中口腔白斑自动检测
Cureus. 2025 May 2;17(5):e83368. doi: 10.7759/cureus.83368. eCollection 2025 May.
2
Oral leukoplakia: still an enigmatic disorder.口腔白斑:仍是一种神秘的疾病。
Med Oral Patol Oral Cir Bucal. 2025 Sep 1;30(5):e730-e735. doi: 10.4317/medoral.27214.
3
Exploring Cancer-Associated Fibroblasts in OSCC and OPMDs: Microenvironment Insights. Scoping Review.探索口腔鳞状细胞癌和口腔潜在恶性疾病中的癌症相关成纤维细胞:微环境见解。范围综述。
Oral Dis. 2025 Feb 10. doi: 10.1111/odi.15275.
4
Investigating Tumor-Infiltrating Lymphocytes in the Microenvironment of Oral Squamous Cell Carcinoma (OSCC) and Oral Potentially Malignant Disorders (OPMDs): Can They Shift Our Perspective? A Scoping Review.口腔鳞状细胞癌(OSCC)和口腔潜在恶性疾病(OPMDs)微环境中肿瘤浸润淋巴细胞的研究:它们能改变我们的观点吗?一项范围综述
J Clin Med. 2025 Jan 18;14(2):606. doi: 10.3390/jcm14020606.
5
Management of oral leukoplakia with an 808-nm high-power diode laser: a single-center experience.808nm 大功率半导体激光治疗口腔白色角化病的单中心经验。
Lasers Med Sci. 2023 Jun 19;38(1):141. doi: 10.1007/s10103-023-03806-1.
6
Recurrence of Oral Leukoplakia after CO Laser Resection: A Prospective Longitudinal Study.CO激光切除术后口腔白斑的复发:一项前瞻性纵向研究
Cancers (Basel). 2022 Nov 6;14(21):5455. doi: 10.3390/cancers14215455.